Compliance · State rules

Office-use compounding in Nevada

Repealed in 2024 for compounded drugs; manufactured office supplies unaffected

USPeptideRx EditorialLast reviewed: August 30, 2026

Nevada used to permit this and repealed it, in two dated steps, in 2024. The rule that allowed a pharmacy to provide compounded drugs to "a practitioner who will be administering the drugs to a patient" had that clause struck by name — Nevada prints deleted material in square brackets, so the deletion is quotable rather than inferred. The half that matters commercially, and that almost every summary of this gets wrong: the repeal bit only on COMPOUNDED product. A Nevada prescriber may still buy office supplies of commercially manufactured drugs from a pharmacy under NRS 639.268(1), which is untouched. Both halves belong in the same breath, because either one alone is a different state’s law.

The governing rule

Nevada’s office-use position is set by NAC 639.757; NRS 639.268(1); repealed by R100-23 and R053-24. The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

Adopted Regulation R053-24, Sec. 27 — the deletion itself, in Nevada’s bracket notation

(b) The compounded drugs are not sold or otherwise provided by the pharmacy , [or] pharmacist or dispensing practitioner to any person other than the ultimate user of the drugs [,] or the agent of the ultimate user of the drugs [or a practitioner who will be administering the drugs to a patient;] ; and

R100-23 — the Legislative Counsel’s Digest, saying it in terms

thereby prohibiting a pharmacy from selling or otherwise providing a compounded drug to a retail pharmacy or practitioner in any circumstance.

NRS 639.268(1) — the half that survived, and it is not about compounded drugs

A practitioner may purchase supplies of controlled substances, poisons, dangerous drugs and devices from a pharmacy

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

What was repealed, and when — both dates or half a factHigh confidence: Two instruments did it. R100-23, effective 14 June 2024, removed the exception, and its Legislative Counsel’s Digest says so in plain words. R053-24, effective 15 November 2024, finished the job by striking the practitioner clause from the operative sentence. The codified section now carries only subsections 1, 2 and 3, and its history line reads for both regulations.The struck wording — "or a practitioner who will be administering the drugs to a patient" — returns zero hits across the whole of NAC chapter 639. This is not a rule that was narrowed or left ambiguous. It was deleted by name.
The half that survived, and why omitting it is the worst error available hereHigh confidence: NRS 639.268(1) lets a practitioner purchase supplies of controlled substances, poisons, dangerous drugs and devices from a pharmacy, by oral order, and it is untouched. NRS 454.221(2)(d) and the purchase-order recordkeeping rule at NAC 454.050 sit alongside it. So Nevada has not closed the prescriber’s supply route; it has closed the compounded half of it.A sentence saying Nevada bans office use, with no mention of the compounded limb, is wrong in the direction that costs a reader money — it would tell a clinic it cannot do something Nevada expressly permits. The defensible construction names both halves: Nevada permits a prescriber to buy office supplies of commercially manufactured drugs from a pharmacy, and repealed the equivalent permission for compounded drugs in two steps in 2024.
What binds nowHigh confidence: The surviving exemption at NAC 639.757(1) holds only where the drugs go to nobody other than the ultimate user or that user’s agent, and are dispensed pursuant to a prescription or chart order. Office stock satisfies neither limb once the practitioner clause is gone.
Sterile and non-sterileHigh confidence: The repealed section drew no distinction — the word "sterile" does not appear in it. A split does exist one layer up and it is worth knowing, because the two texts disagree: NAC 639.6912 defines an outsourcing facility in terms of compounding sterile drugs, while NRS 639.268(8)(b) speaks of "sterile or nonsterile".
Quantity and labellingHigh confidence: No numeric cap survives. The office-use-specific cap went with the repeal, leaving the qualitative standard that quantities be reasonably necessary based upon the previous history. There is no label legend: "office use", "office stock" and "not for resale" return zero hits across all of NAC 639, against working controls in the same search.
The 5% clause has no practitioner limb at allHigh confidence: NRS 639.0155(4) runs retail pharmacy to retail pharmacy, to alleviate a temporary shortage. It does not mention practitioners, so unlike almost every other state in this file, Nevada’s version cannot even be waved at a physician — there is nothing in it to misread.
Entity or personMedium confidence: The person by default. Possession and administration authority runs to "a practitioner", and the definitions of practitioner at NRS 639.0125 and NRS 454.00958 carry a licensure precondition in their entity limbs — an entity qualifies only once it is itself licensed or registered.
What the Board has said in plain EnglishHigh confidence: A Board letter of 2 June 2025, issued over the Executive Secretary’s name inside a compounded GLP-1 enforcement letter, reminds 503A pharmacies that they are not permitted to sell compounded medications to practitioners. It states the position directly and it is the regulator’s own writing.This is sub-regulatory guidance, not law, and it is reported that way deliberately. It is evidence of how the Board reads its own rule; it is not the rule.
Two pending items, and one of them is a decoyMedium confidence: R106-26, filed 22 May 2026, reads like a reopening and is not one: it is patient-specific white-bagging, with written patient consent, separate storage and a 90-day burn-down. R158-26, an initial agency draft filed 30 June 2026, would require Board authorisation to compound at all and does not touch the repealed section. Neither has an effective date.The white-bagging proposal is the one most likely to be misreported as Nevada changing its mind. It is a different arrangement with a patient named on it.
Last changeHigh confidence: The repeal completed 15 November 2024. Nothing since has restored a practitioner limb, and neither pending item would.

Nevada at a glance

Nevada office-use compounding summary, reviewed 2026-08-30
Human office use	Repealed 2024 for compounded drugs; manufactured office supplies unaffected
Sterile preparations	No split in the repealed section
Quantity cap	None — the office-use cap went with the repeal
Mandatory label legend	None; the terms appear nowhere in the chapter
Board reporting	None for office use; there is no permitted activity to report
Last change	Repeal completed November 2024
Governing rule	NAC 639.757; NRS 639.268(1); repealed by R100-23 and R053-24

Receiving 503B office stock in Nevada

Nevada requires a state credential of any facility compounding sterile drugs for shipment into the state, but it does not call it an outsourcing-facility licence — it calls it a manufacturer licence, so the category a reader searches for returns nothing.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Nevada asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence: A manufacturer licence from the Board of Pharmacy. NAC 639.6915 requires it of a facility compounding sterile drugs or compounding for shipment into the state, and no outsourcing-facility category exists in Nevada law at all.The fee is genuinely unresolved and is therefore not stated as a figure here: the codified schedule at NAC 639.220 says one amount and the Board’s own out-of-state application form says half of it. Publishing either as settled would be inventing certainty the state has not provided.
Does your practice need a permit?High confidence: Not to possess or administer. NRS 454.213(1)(a) grants that to a practitioner outright. A $300 Dispensing Practitioner Registration under NRS 639.23505 is required per office, but only where the practice both dispenses AND charges for the drug — administering in the office triggers neither.
Administer vs dispenseHigh confidence: The line is drawn at charging as well as at dispensing, which is unusual. A practice that administers is outside the registration entirely; one that dispenses and bills for the product is inside it, per office rather than per practitioner.
Scheduled (controlled) stockMedium confidence: Yes — a Board of Pharmacy registration, biennial, per principal place of business, with proof of access to the prescription monitoring programme a precondition under NRS 453.226.Whether the state registration must precede the federal one was not established for Nevada, unlike several states in this file where the sequence is documented. Do not assume it follows the same order.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Federal law is a second, independent constraint — a state prohibition is not the only thing standing in the way. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Nevada compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

We located no Board declaratory ruling or order construing the phrase "agent of the ultimate user". A reading of that phrase which reached an administering practitioner would materially soften this verdict, and we did not sweep the Board’s meeting books and recordings — the minutes are summary-style, so a substantive discussion could exist only there.
The 503B fee is unreconciled between the codified schedule and the Board’s own application form, so no figure is published here. The in-state application is available only by email request.
Whether a med spa falls into a Nevada medical-facility licensure category carrying drug-handling conditions is outside what this page examined. The finding that no receiver-side tax exists covers the pharmacy, controlled-substance and dangerous-drug chapters only.
We searched no case law, attorney-general opinions or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.